ObsEva Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ObsEva stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OBSV, but not buy additional shares or sell existing shares.
View analyst ratings for ObsEva or view top-rated stocks.

Wall Street analysts have given ObsEva a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ObsEva wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

ObsEva saw a increase in short interest in January. As of January 29th, there was short interest totaling 2,290,000 shares, an increase of 84.7% from the January 14th total of 1,240,000 shares. Based on an average daily trading volume, of 4,810,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 7.3% of the shares of the company are short sold.
View ObsEva's Short Interest.

ObsEva is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for ObsEva.

ObsEva SA (NASDAQ:OBSV) issued its quarterly earnings results on Thursday, November, 5th. The company reported ($0.49) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.15.
View ObsEva's earnings history.

ObsEva's stock was trading at $2.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OBSV stock has increased by 31.1% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued twelve-month price targets for ObsEva's stock. Their forecasts range from $4.00 to $28.00. On average, they expect ObsEva's share price to reach $11.80 in the next year. This suggests a possible upside of 250.1% from the stock's current price.
View analysts' price targets for ObsEva or view top-rated stocks among Wall Street analysts.

Some companies that are related to ObsEva include Akouos (AKUS), Atreca (BCEL), Intercept Pharmaceuticals (ICPT), Magenta Therapeutics (MGTA), BELLUS Health (BLUSF), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX), Inventiva (IVA), Clovis Oncology (CLVS), Chimerix (CMRX), KalVista Pharmaceuticals (KALV), Flexion Therapeutics (FLXN), Geron (GERN), IDEAYA Biosciences (IDYA) and Eagle Pharmaceuticals (EGRX).
View all of OBSV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

ObsEva's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (3.98%), Renaissance Technologies LLC (1.25%), Credit Suisse AG (1.24%), Zurcher Kantonalbank Zurich Cantonalbank (0.74%), Barclays PLC (0.36%) and Cutter & CO Brokerage Inc. (0.29%).

OBSV stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP.

OBSV stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Renaissance Technologies LLC, Barclays PLC, Cutter & CO Brokerage Inc., Zurcher Kantonalbank Zurich Cantonalbank, Virtu Financial LLC, GSA Capital Partners LLP, and Credit Suisse AG.

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OBSV stock can currently be purchased for approximately $3.37.

ObsEva has a market capitalization of $161.76 million. The company earns $-108,790,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis.

ObsEva employs 53 workers across the globe.

The official website for ObsEva is www.obseva.com.

ObsEva is headquartered at Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228.

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]